Status:
TERMINATED
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV Infections
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several differ...
Eligibility Criteria
Inclusion
- Demonstrates good general health
- Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), and Hepatitis C (HCV) seronegative
- Low risk of acquiring HIV infection
- ALT lab value within normal range
Exclusion
- Previously received an investigational HIV vaccine
- Has a known or suspected impairment of immunologic function
- Has a clinically significant chronic medical condition that is considered progressive
- Has a major psychiatric illness
- Has any history of malignancy, with the exception of basal cell or squamous cell skin cancer
- Weighs less than 105 lbs.
- Has a recent (within two years) history of chronic alcohol abuse
- Has a contraindication to intramuscular (IM) injection, such as anticoagulant therapy or thrombocytopenia
- Female is pregnant or breast feeding, or expecting to conceive or donate eggs during the study
- Male subject is planning to impregnate or provide sperm donation during the study
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT00350623
Start Date
October 1 2006
End Date
May 1 2008
Last Update
August 25 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.